Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 11:00 AM
Ignite Modification Date:
2025-12-26 @ 11:00 AM
NCT ID:
NCT04730206
Eligibility Criteria:
Inclusion Criteria:
* Aged 40 years or older;
* At least 2 Covid-19 suggestive symptoms at the time of inclusion, with onset of a maximum of 5 days prior to enrolment, and which cannot be explained by an alternative cause, and defined by the current Sciensano case definition
* Positive result on PCR test or rapid Ag test in the 7 days before inclusion or at the time of inclusion;
* Patient is community dwelling;
* Participant or their proxy is willing and able to give informed consent for participation in the trial;
* Participant is willing to comply with all trial procedures.
Exclusion Criteria:
* Hospital admission is required at the time of possible recruitment;
* Positive PCR or rapid antigen test for SARS-CoV-2 in the last 2 months other than a test at recruitment or in the 7 days prior to recruitment;
* Participating in any other interventional drug clinical study before enrolment in the study;
* Breastfeeding;
* Known severe neurological disorder, especially seizures in the last 12 months;
* Known allergy to camostat or molnupiravir;
* Previous adverse reaction to, or currently taking, camostat or molnupiravir;
* Patients in palliative care;
* Pregnant women or women of childbearing potential who may become pregnant during the trial and don't agree to use any of the effective contraceptive measures lised above;
* Judgement of the recruiting clinician deems participant ineligible.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT04730206
Study Brief:
Protocol Section:
NCT04730206